Shots:

• The P-III IMagyn050 study involves assessing of Tecentriq + Avastin- paclitaxel- and carboplatin vs PBO + Avastin- paclitaxel and carboplatin in the ratio (1:1) in women with Stage III or IV ovarian cancer who are undergoing neoadjuvant or adjuvant therapy
• The study did not meet its 1EP i.e. PFS while the safety data were consistent with the safety profile of the combination  
• Tecentriq is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptors. Additionally- Roche collaborated with The GOG Foundation and European Network of Gynaecological Oncological Trial groups (ENGOT) [ENGOT OV-39] to conduct P-III IMagyn050 Trial

Click here to read full press release/ article

Ref: Roche | Image: Roche